JP2018509390A5 - - Google Patents

Download PDF

Info

Publication number
JP2018509390A5
JP2018509390A5 JP2017540167A JP2017540167A JP2018509390A5 JP 2018509390 A5 JP2018509390 A5 JP 2018509390A5 JP 2017540167 A JP2017540167 A JP 2017540167A JP 2017540167 A JP2017540167 A JP 2017540167A JP 2018509390 A5 JP2018509390 A5 JP 2018509390A5
Authority
JP
Japan
Prior art keywords
seq
sequence
binding fragment
antigen
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540167A
Other languages
English (en)
Japanese (ja)
Other versions
JP6942633B2 (ja
JP2018509390A (ja
Filing date
Publication date
Priority claimed from US14/723,297 external-priority patent/US10023892B2/en
Priority claimed from US14/798,312 external-priority patent/US10150818B2/en
Application filed filed Critical
Priority claimed from PCT/US2016/015858 external-priority patent/WO2016123593A1/en
Publication of JP2018509390A publication Critical patent/JP2018509390A/ja
Publication of JP2018509390A5 publication Critical patent/JP2018509390A5/ja
Application granted granted Critical
Publication of JP6942633B2 publication Critical patent/JP6942633B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540167A 2015-01-30 2016-01-30 抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法 Active JP6942633B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562110338P 2015-01-30 2015-01-30
US62/110,338 2015-01-30
US14/723,297 US10023892B2 (en) 2014-05-27 2015-05-27 Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US14/723,297 2015-05-27
US14/798,312 US10150818B2 (en) 2014-01-16 2015-07-13 Compositions and methods for treatment and detection of cancers
US14/798,312 2015-07-13
PCT/US2016/015858 WO2016123593A1 (en) 2015-01-30 2016-01-30 Compositions and methods relating to universal glycoforms for enhanced antibody efficacy

Publications (3)

Publication Number Publication Date
JP2018509390A JP2018509390A (ja) 2018-04-05
JP2018509390A5 true JP2018509390A5 (enExample) 2019-02-28
JP6942633B2 JP6942633B2 (ja) 2021-09-29

Family

ID=56544456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540167A Active JP6942633B2 (ja) 2015-01-30 2016-01-30 抗体の増強された有効性のための普遍的グリコフォームに関する組成物および方法

Country Status (11)

Country Link
EP (1) EP3250590B1 (enExample)
JP (1) JP6942633B2 (enExample)
KR (1) KR102620346B1 (enExample)
CN (2) CN114702581B (enExample)
AU (1) AU2016211176B2 (enExample)
CA (1) CA2973886A1 (enExample)
DK (1) DK3250590T3 (enExample)
ES (1) ES2901173T3 (enExample)
IL (1) IL253497B2 (enExample)
TW (1) TWI717333B (enExample)
WO (2) WO2016123591A2 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170010003A (ko) * 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
EP3344806A4 (en) 2015-09-04 2019-03-20 OBI Pharma, Inc. GLYCANARRAYS AND METHOD OF USE
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
AU2017239637A1 (en) 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
IL262296B2 (en) 2016-04-22 2024-09-01 Obi Pharma Inc Cancer immunotherapy by immune activation or immune modulation via globo series antigens
KR20190067765A (ko) 2016-07-27 2019-06-17 오비아이 파머 인코퍼레이티드 면역원성/치료 글리칸 조성물 및 그의 용도
KR102528998B1 (ko) 2016-07-29 2023-05-03 오비아이 파머 인코퍼레이티드 인간 항체, 제약 조성물 및 방법
CN107778372B (zh) * 2016-08-22 2019-11-26 中国科学院上海药物研究所 一种寡糖连接子以及利用该寡糖连接子制备的定点连接的抗体-药物偶联物
JP7373998B2 (ja) 2017-05-02 2023-11-06 コーネル・ユニバーシティー 有効性がより大きくかつ毒性がより少ない腫瘍標的指向方法及び試薬
CN112312924A (zh) * 2018-06-01 2021-02-02 台湾浩鼎生技股份有限公司 通过使用抗Globo H或抗SSEA-4抗体与抗负面免疫检查点抗体的联合疗法
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
CN109620970A (zh) * 2018-11-13 2019-04-16 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 一种胸腔镜下内乳区前哨淋巴结纳米碳示踪活检及内乳淋巴结清扫方法
CN114026229B (zh) 2019-08-05 2025-03-25 醣基生医股份有限公司 用于重塑抗体醣型之融合蛋白
AU2021376384B2 (en) 2020-11-06 2026-04-16 Cho Pharma, Inc. Immune composition comprising antigen and glycoengineered antibody thereof
CN116615461A (zh) * 2020-11-30 2023-08-18 醣基生医股份有限公司 用于富集细胞的抗体

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US351A (en) 1837-08-15 James wilson
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5112596A (en) 1990-04-23 1992-05-12 Alkermes, Inc. Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU8295491A (en) 1990-06-29 1992-01-23 Biosource Technologies Incorporated Melanin production by transformed microorganisms
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE69222303T2 (de) 1991-04-30 1998-01-22 Eukarion Inc Kationisierte antikörper gegen intrazelluläre eiweisse
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
CA2372813A1 (en) 1992-02-06 1993-08-19 L.L. Houston Biosynthetic binding protein for cancer marker
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002610A1 (en) 1992-07-17 1994-02-03 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
AU677216B2 (en) 1992-07-27 1997-04-17 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Targeting of liposomes to the blood-brain barrier
DE69308573T2 (de) 1992-08-17 1997-08-07 Genentech Inc Bispezifische immunoadhesine
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
US7863020B2 (en) * 2000-06-28 2011-01-04 Glycofi, Inc. Production of sialylated N-glycans in lower eukaryotes
US6514221B2 (en) 2000-07-27 2003-02-04 Brigham And Women's Hospital, Inc. Blood-brain barrier opening
AU2001286930A1 (en) 2000-08-30 2002-03-13 The Board Of Trustees Of The Leland Stanford Junior University Glucocorticoid blocking agents for increasing blood-brain barrier permeability
US7034036B2 (en) 2000-10-30 2006-04-25 Pain Therapeutics, Inc. Inhibitors of ABC drug transporters at the blood-brain barrier
US20030083299A1 (en) 2000-11-04 2003-05-01 Ferguson Ian A. Non-invasive delivery of polypeptides through the blood-brain barrier
US20030104402A1 (en) 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
DE10121982B4 (de) 2001-05-05 2008-01-24 Lts Lohmann Therapie-Systeme Ag Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung
CA2450073C (en) 2001-07-25 2017-08-29 Biomarin Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US20030162695A1 (en) 2002-02-27 2003-08-28 Schatzberg Alan F. Glucocorticoid blocking agents for increasing blood-brain barrier permeability
AU2003219277A1 (en) 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
JP4995423B2 (ja) 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
US7355008B2 (en) * 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005025511A2 (en) 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Potassium channel mediated delivery of agents through the blood-brain barrier
AU2007325283B2 (en) * 2006-11-27 2012-08-30 Diadexus, Inc. Ovr110 antibody compositions and methods of use
ES2474940T3 (es) * 2006-12-28 2014-07-10 Janssen Biotech, Inc. Métodos y vectores que generan inmunoglobulinas sialiladas
CA2712562A1 (en) * 2007-01-18 2008-07-24 Glykos Finland Ltd Novel specific cell binders
JP2010526066A (ja) * 2007-04-23 2010-07-29 シェーリング コーポレイション 抗mdl−1抗体
JP2011524375A (ja) 2008-06-16 2011-09-01 アカデミア シニカ GloboHおよびSSEA3に特異的な免疫反応を誘起する組成物および癌治療におけるその使用
MX2010013931A (es) 2008-06-16 2011-06-01 Academia Sinica Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos.
JP2010014691A (ja) * 2008-06-20 2010-01-21 Igaku Seibutsugaku Kenkyusho:Kk 腹水中のメソテリン及び/又は巨核球増強因子を検出するための方法、キット、試薬及び装置
CN102215862B (zh) * 2009-06-16 2016-04-06 中央研究院 Globo h及含新颖糖脂质佐剂的相关抗癌疫苗
US10087236B2 (en) * 2009-12-02 2018-10-02 Academia Sinica Methods for modifying human antibodies by glycan engineering
JPWO2011074621A1 (ja) * 2009-12-18 2013-04-25 株式会社医学生物学研究所 メソセリン(msln)に対する抗体及びその用途
NZ601580A (en) * 2010-02-11 2014-11-28 Alexion Pharma Inc Therapeutic methods using anti-cd200 antibodies
GB201015569D0 (en) * 2010-09-16 2010-10-27 Medical Res Council Blood assay for prions
AU2012258907A1 (en) * 2011-05-25 2013-11-07 Merck Sharp & Dohme Corp. Method for preparing Fc-containing polypeptides having improved properties
JP6282232B2 (ja) * 2012-02-10 2018-02-21 ユニバーシティー オブ メリーランド,ボルティモア 抗体及びそのFcフラグメントの酵素化学的糖鎖改変
WO2013151649A1 (en) * 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
TWI573876B (zh) 2012-08-20 2017-03-11 中央研究院 寡醣之大規模酵素合成
WO2014078373A1 (en) * 2012-11-13 2014-05-22 Iogenetics, Llc Antimicrobial compositions
KR20160104727A (ko) * 2014-01-16 2016-09-05 아카데미아 시니카 암의 치료 및 검출을 위한 조성물 및 방법
WO2016114819A1 (en) * 2015-01-16 2016-07-21 Academia Sinica Compositions and methods for treatment and detection of cancers
KR20170010003A (ko) 2014-05-27 2017-01-25 아카데미아 시니카 박테로이드 기원의 푸코시다제 및 이의 사용 방법
US10118969B2 (en) * 2014-05-27 2018-11-06 Academia Sinica Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP6588084B2 (ja) * 2014-08-19 2019-10-09 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング Ssea4抗原に特異的なキメラ抗原受容体
US9975965B2 (en) * 2015-01-16 2018-05-22 Academia Sinica Compositions and methods for treatment and detection of cancers

Similar Documents

Publication Publication Date Title
IL253497B2 (en) Formulations and methods related to universal glycoforms for enhanced antibody efficacy
JP2020500003A5 (enExample)
JP2018509385A5 (enExample)
JP2021531254A5 (enExample)
JP2023509196A5 (enExample)
JP2017507118A5 (enExample)
JP2013502913A5 (enExample)
CN103068851B (zh) 内质蛋白的抗体及其用途
TWI777056B (zh) 結合至ssea4的單株抗體及其用途
JP2023540526A5 (enExample)
HRP20180507T1 (hr) Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju
JP2009521496A5 (enExample)
JP2017507652A5 (enExample)
HRP20192280T1 (hr) Anti-ceacam6 protutijela i njihova uporaba
JP2013508292A5 (enExample)
CA2523449A1 (en) Recombinant antibodies and fragments which recognize n glycolil gm3 ganglioside and its use in diagnosis and treatment of tumours
JP2016533721A5 (enExample)
RU2014101707A (ru) АНТИ-Axl АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ
US20170204184A1 (en) Anti-pd-l1 antibodies
RU2018100824A (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина
JP2016094424A5 (enExample)
JP2020533965A5 (enExample)
JP2020522488A5 (enExample)
JP2015528802A5 (enExample)
JP2023509373A5 (enExample)